In order verify the fibrinolytic activity of our TNK and tPA treatments, we conducted a delay of clot formation assay (in the absence of cancer cells) in the presence of 1, 0.5, and 0.25 μg·mL−1 concentrations of both fibrinolytic agents and thrombin (Fig. S4). Here, PLAT is linked to cancer.